Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug990 | Common Elements Toolbox- Adult version (COMET-A) Wiki | 1.00 |
| drug4761 | survey Wiki | 0.38 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The investigators are evaluating the acceptability and effectiveness of brief online wellness modules. Participants will be randomly assigned to the intervention condition, an active control condition, or a wait-list control condition. The investigators are using a factorial design, such that each participant in the intervention condition will be randomly assigned to receive three of four wellness modules. The investigators will analyze the intervention's effectiveness as a universal intervention (using the full sample) and a targeted intervention (using the subset of the sample that reported elevated depressive symptoms or anxiety symptoms at baseline).
Description: Depression questionnaire. Scores range from 0 to 27. Lower scores indicate less depression.
Measure: Change in Patient Health Questionnaire-9 (PHQ-9) Time: Up to 12 weeks post-interventionDescription: Anxiety questionnaire. Total scores range from 0-21. Lower scores indicate less anxiety.
Measure: Change in Generalized Anxiety Disorder Screener-7 (GAD-7) Time: Up to 12 weeks post-interventionDescription: Subjective Well-being questionnaire. Total scores range from 7 to 35. Higher values indicate higher well-being scores.
Measure: Change in Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) Time: Up to 12 weeks post-interventionDescription: Questionnaire measuring the acceptability of an intervention. Acceptability refers to the perception that a given treatment is agreeable or satisfactory. The total score ranges from 4 to 20. Higher scores indicate higher acceptability ratings.
Measure: Ratings of Acceptability of Intervention Measure (AIM) Time: Immediately after the interventionDescription: Participants answered questions relating to each module's mechanism of change on a 7-point Likert Scale, from "strongly disagree" to "strongly agree". Specifically, we asked participants: How capable they feel about managing negative thoughts If they will intentionally spend time doing activities they enjoy If they will notice and appreciate good things If they will be able to treat themselves with empathy and compassion
Measure: Mechanism Questions Time: Up to 12 weeks post-interventionDescription: 2 questions related to their ability to cope with stressors over the upcoming weeks (including challenges relating to COVID-19). Participants answered these questions on a 7-point Likert Scale, from "strongly disagree" to "strongly agree". Specifically, we asked participants: if they will be able to handle lifestyle changes due to the coronavirus, if the pandemic will have an extremely negative impact on their life.
Measure: Ability to Cope with COVID-19 Time: Up to 12 weeks post-interventionDescription: We asked participants three items to assess secondary control (Weisz et al., 2010). The items are scored on a 4-point Likert scale, ranging from 0 ("Very false") to 3 ("Very true"). The three items are: When something bad happens, I can find a way to think about it that makes me feel better. After a really hard day, I can make myself feel better by remembering some good things that happened. When bad things happen to me that I can't control, there are lots of things I can do to feel better. Higher scores will indicate greater secondary control.
Measure: Secondary Control Time: Up to 12 weeks post-interventionDescription: Participants were asked to rate three items relating to the perceived utility of each module. Specifically, we asked participants: How helpful the module was How engaging the module was How much they will continue applying content from the module Higher scores will indicate greater perceived utility.
Measure: Perceived Utility Time: Immediately after the interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports